SCHEMBL2237831

SCHEMBL2237831

C=CCCCCO[C@H](COCCCCCCCC)COP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.70
AKT1 P31749 2/20 0.70
LMNA P02545 2/20 0.70
MEN1 O00255 2/20 0.70
KMT2A Q03164 2/20 0.70
PRKD3 O94806 1/20 0.70
PRKCG P05129 1/20 0.70
PRKCB P05771 1/20 0.70
PRKCA P17252 1/20 0.70
PRKCH P24723 1/20 0.70
PRKCI P41743 1/20 0.70
PRKCE Q02156 1/20 0.70
PRKCQ Q04759 1/20 0.70
PRKCZ Q05513 1/20 0.70
PRKCD Q05655 1/20 0.70
PRKD1 Q15139 1/20 0.70
MAPK1 P28482 1/20 0.70
SMN1; SMN2 Q16637 1/20 0.70
GMNN O75496 1/20 0.70
BLM P54132 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2231020 1.00 ALDH1A1 (0.70) ALDH1A1AKT1LMNAMEN1KMT2A
SCHEMBL93895 1.00 ALDH1A1 (0.70) ALDH1A1AKT1LMNAMEN1KMT2A
SCHEMBL93768 1.00 ALDH1A1 (0.70) ALDH1A1AKT1LMNAMEN1KMT2A
SCHEMBL29365750 0.91 ALDH1A1 (0.73) ALDH1A1AKT1LMNAMEN1KMT2A
SCHEMBL29394546 0.91 ALDH1A1 (0.73) ALDH1A1AKT1LMNAMEN1KMT2A
SCHEMBL29905581 0.91 ALDH1A1 (0.73) ALDH1A1AKT1LMNAMEN1KMT2A
SCHEMBL93475 0.91 ALDH1A1 (0.73) ALDH1A1AKT1LMNAMEN1KMT2A
SCHEMBL94022 0.91 ALDH1A1 (0.73) ALDH1A1AKT1LMNAMEN1KMT2A
SCHEMBL53200 0.91 ALDH1A1 (0.73) ALDH1A1AKT1LMNAMEN1KMT2A
SCHEMBL4320248 0.91 AKT1 (0.83) ALDH1A1AKT1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206206-B2 Oxidized lipid compounds and uses thereof VASCULAR BIOGENICS LTD. (IL) 2015-12-08 US disclosed
EP-2826369-A2 Oxidized lipid compounds and uses thereof Vascular Biogenics Ltd. (IL) 2015-01-21 EP disclosed
EP-2826370-A2 Oxidized lipid compounds and uses thereof Vascular Biogenics Ltd. (IL) 2015-01-21 EP disclosed
EP-2348866-B1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD (IL) 2015-01-07 EP disclosed
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof VASCULAR BIOGENICS LTD. (IL) 2013-08-08 US disclosed
CN-102271517-A oxidized lipid compounds and uses thereof 2011-12-07 CN disclosed
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130203707-A1 Oxidized Lipid Compounds and Uses Thereof LPO, GPX4, ALOX15B ALDH1A1 616/4885AKT1 4087/4885LMNA 2239/4885
US-20110207703-A1 OXIDIZED LIPID COMPOUNDS AND USES THEREOF LPO, GPX4, ALOX15B ALDH1A1 616/4885AKT1 4087/4885LMNA 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.